ARX Promotes Digital Signatures at China's SFDA Conference

Share Article

Dr. Gadi Aharoni, CEO of digital signature solutions provider, ARX, will join other life science industry leaders for a week long training session for the Chinese State Food and Drug Administration (SFDA) and other stakeholders in the growing Chinese pharmaceutical supply marketplace. The event will be held December 15-19, 2007 in Hainan, China.

Dr. Gadi Aharoni, CEO of digital signature solutions provider, ARX, will join other life science industry leaders for a week long training session for the Chinese State Food and Drug Administration (SFDA) and other stakeholders in the growing Chinese pharmaceutical supply marketplace. The event will be held December 15-19, 2007 in Hainan, China.

The event focuses on Good Clinical Practice (GCP) compliance and related GxP topics such as good documentation best practices, preparation for regulatory audits, and current technology trends particularly in the clinical trial space. Dr. Aharoni will discuss the best practice of using digital signatures (standard electronic signatures) within an enterprise or even cross enterprise-wide strategy for regulatory compliance and other tangible business benefits such as expedited processes, reduced operational costs, and the added value of "going green" with paperless operations.

The timing of this event follows a year marked by well-publicized food and drug safety concerns that have damaged China's credibility on the international stage. In the past year the Chinese SFDA has revoked licenses of several drug manufacturers since last July, and also withdrawn the Good Manufacturing Practice (GMP) certificates from over 100 drug makers greatly reducing their capability to export active pharmaceutical ingredients (APIs) to the rest of the world. This past summer Zheng Xiaoyu, former director of SFDA, was sentenced to death by a Beijing court citing dereliction of duty as one of numerous charges against him.

The SFDA is now expanding the number of GMP inspectors in pharmaceutical factories and monitoring the production quality of drug manufacturers across the country. The SFDA Training event is another step towards educating the Chinese food and pharmaceutical market on the best practices and technology trends - such as the use of digital signatures - in other parts of the world. The primary sponsor for this event is clinical trial data services provider Medidata Solutions, and includes many recognized industry thought leaders with expertise in GxP and related technology strategies. Dr. Aharoni was recognized in 2006 as one of the Top 100 Influencers by readers of PharmaVoice, and ARX is recognized as a leading digital signature solutions provider within the life sciences sector.

About CoSign
The CoSign approach means digital signature standards and efficiencies across your operations. Signing and sealing documents with CoSign immediately expedites business processes, reduces costs, increases security and enables organizations to comply with diverse regional and industry regulations. CoSign works with all major applications and document formats including: Microsoft® Word, Excel®, Outlook®, Adobe® PDF, TIFF, AutoCAD®, InfoPath®, Lotus Forms, and many more). CoSign signatures are being used by hundreds of thousands of users in Enterprise, B2B and B2C processes, to learn why please see our white papers and product details at http://www.arx.com/products/cosign-digital-signatures.php

About ARX (Algorithmic Research)
ARX has over 20 years of experience assisting banking, financial services, life sciences, healthcare, governmental organizations and commercial sectors to secure and streamline their business processes and transactions. ARX offers a wide range of highly scalable products designed to simplify, secure, and accelerate electronic business. ARX successfully completed its MBO acquisition from Cylink Corporation, today SafeNet, Inc. (NASDAQ:SFNT) in 2001. For more information, please visit http://www.arx.com

CoSign® is a registered trademark of Algorithmic Research, Ltd. All other trade names and trademarks are the property of their respective holders.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

RUSSEL HARRIS
ARX
+972526100142
Email >
Visit website

Media